Showing results (641-650 of 794) with videos related to

Sort By:
Pageof 80
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 14, 2018
Low Tristetraprolin Expression Is Associated with Lethal Prostate CancerTravis Gerke, Himisha Beltran, Xiaodong Wang, et al.
Urologic Oncology|May 21, 2015
Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imagingVinayak Muralidhar, Kathryn T Dinh, Brandon A Mahal, et al.
The American Journal of Medicine|March 21, 2018
Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent DivorceKathryn T Dinh, Ayal A Aizer, Vinayak Muralidhar, et al.
Clinical Genitourinary Cancer|May 3, 2017
Disparities in the Receipt of Local Treatment of Node-positive Prostate CancerVinayak Muralidhar, Brandon A Mahal, Brent S Rose, et al.
The Journal of Bone and Joint Surgery. American Volume|November 8, 2014
Improving residency training in arthroscopic knee surgery with use of a virtual-reality simulator. A randomized blinded studyW Dilworth Cannon, William E Garrett, Robert E Hunter, et al.
Cancer Research|March 27, 2015
PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapyChen-Lin Hsieh, Ginevra Botta, Shuai Gao, et al.
BJU International|August 4, 2015
Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancerVinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, et al.
Urologic Oncology|October 13, 2014
Income inequality and treatment of African American men with high-risk prostate cancerDavid R Ziehr, Brandon A Mahal, Ayal A Aizer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancerW Xie, P Ravi, M Buyse, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2019
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trialMichael J Morris, Yohann Loriot, Christopher J Sweeney, et al.
Pageof 80